title: Randomized trial of phosphodiesterase inhibitors versus catecholamines in patients with acutely decompensated heart failure.
abstract: Increased neurohormone and cytokine concentrations are associated with adverse outcome in patients with congestive heart failure, so minimizing these increases may improve outcome, even in the acute phase of decompensated heart failure. The present study was designed to test the hypothesis that phosphodiesterase inhibitors, but not catecholamines, could favorably affect neurohormone and cytokine profiles in patients with acutely decompensated heart failure. Twenty-nine patients underwent monitoring using a Swan-Ganz catheter and were randomly allocated to receive phosphodiesterase inhibitors (PDEI group, n=19) or catecholamines (CA group, n=10). Pulmonary capillary wedge pressure decreased significantly in both groups and cardiac output showed a slight, but not statistically significant increase, in both groups. There was a significant decrease in plasma brain natriuretic peptide concentration in the PDEI group, but not in the CA group, whereas plasma interleukin-6 concentration increased in the CA group, but not in the PDEI group. Phosphodiesterase inhibitors favorably affect neurohormone and cytokine concentrations in patients with acutely decompensated heart failure.
authors.affiliation: Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Kawamura
authors.forename: T
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Hayashi
authors.forename: E
authors.initials: E
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Anzai
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: S
authors.initials: S
authors.lastname: Ogawa
mesh_terms: D000208:Acute Disease; D000368:Aged; D002302:Cardiac Output / Q000187:drug effects; D002395:Catecholamines / Q000008:administration & dosage / Q000494:pharmacology*; D016207:Cytokines / Q000097:blood / Q000187:drug effects; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000097:blood; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects
chemical_list: D002395:Catecholamines; D016207:Cytokines; D015850:Interleukin-6; D018377:Neurotransmitter Agents; D010726:Phosphodiesterase Inhibitors; D020097:Natriuretic Peptide, Brain